➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
AstraZeneca
McKinsey
Medtronic
McKesson

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXENATIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Exenatide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT04520490 Brain Activation and Satiety in Children 2 Not yet recruiting University of Washington Phase 3 2020-09-01 Childhood obesity and related long-term effects are serious public health problems, but not all obese children do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
New Combination NCT04520490 Brain Activation and Satiety in Children 2 Not yet recruiting Seattle Children's Hospital Phase 3 2020-09-01 Childhood obesity and related long-term effects are serious public health problems, but not all obese children do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Exenatide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082381 Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 2003-06-01 This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082381 Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin Completed AstraZeneca Phase 3 2003-06-01 This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 2003-11-01 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed AstraZeneca Phase 3 2003-11-01 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00085969 Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus Completed Eli Lilly and Company Phase 2 2003-09-01 The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
NCT00085969 Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus Completed AstraZeneca Phase 2 2003-09-01 The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
NCT00097500 Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2004-09-01 This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exenatide

Condition Name

Condition Name for Exenatide
Intervention Trials
Type 2 Diabetes Mellitus 63
Type 2 Diabetes 43
Diabetes Mellitus, Type 2 33
Obesity 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exenatide
Intervention Trials
Diabetes Mellitus 156
Diabetes Mellitus, Type 2 142
Diabetes Mellitus, Type 1 17
Obesity 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exenatide

Trials by Country

Trials by Country for Exenatide
Location Trials
United States 858
Canada 53
China 39
Mexico 35
United Kingdom 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exenatide
Location Trials
Texas 55
California 44
Florida 40
New York 34
Washington 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exenatide

Clinical Trial Phase

Clinical Trial Phase for Exenatide
Clinical Trial Phase Trials
Phase 4 84
Phase 3 66
Phase 2/Phase 3 9
[disabled in preview] 80
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exenatide
Clinical Trial Phase Trials
Completed 154
Recruiting 64
Not yet recruiting 29
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exenatide

Sponsor Name

Sponsor Name for Exenatide
Sponsor Trials
AstraZeneca 78
Eli Lilly and Company 74
Amylin Pharmaceuticals, LLC. 20
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exenatide
Sponsor Trials
Other 263
Industry 223
NIH 16
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Boehringer Ingelheim
Merck
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.